CRISPR cures progeria in mice, raising hope for one-time therapy for a disease that causes rapid aging
By Sharon Begley,
STAT
| 01. 06. 2021
Biologists tend not to discuss experimental results on a handful of cells and a single solitary mouse — too preliminary, too sketchy. David Liu of the Broad Institute therefore had no plans to present such findings, which he’d peeked at over his graduate student’s shoulder, when he gave a high-profile talk in 2018 at the National Institutes of Health on a form of the CRISPR genome-editing system that he’d invented.
Not that he wasn’t tempted. Student Luke Koblan had used the clever new form of CRISPR, called base editing, to alter a single misspelled pair of “letters” among the 3 billion in the DNA of cells taken from children with progeria, an infamous and fatal genetic disease marked by accelerated aging. Koblan had done this work in lab dishes, and had also corrected the progeria mutation in a mouse carrying the human gene that, as a result, aged so quickly that by toddlerhood, it was like a picture of Dorian Gray with whiskers.
Chatting before his talk with NIH Director Francis Collins, who discovered the progeria mutation in 2003, Liu...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...